Antibodies
5 September 2014
TRACON Pharmaceuticals Initiates Phase 2 Clinical Trial of TRC105 in Patients With Soft Tissue Sarcoma5 September 2014
FDA Removes Partial Clinical Hold on OncoMed’s Ipafricept5 September 2014
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy3 September 2014
Visterra to Present Data at ICAAC on VIS513, Its Humanized Monoclonal Antibody That Targets a Conserved Site on the Dengue Virus E Protein3 September 2014
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis3 September 2014
Teva’s Reslizumab Delivers Clinically and Statistically Significant Reduction in Asthma Exacerbations in Two Pivotal Phase III Studies28 August 2014
OncoMed Pharmaceuticals Announces Removal of Partial Clinical Hold by the FDA for Vantictumab27 August 2014
Green Cross Initiates Phase II Trial of Investigational Recombinant Hepatitis B Immune Globulin20 August 2014
Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody18 August 2014
Initiation of Phase 3 Trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody)15 August 2014
FDA approves Roche’s Avastin plus chemotherapy for treatment of advanced cervical cancer14 August 2014
Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy13 August 2014
Celltrion files for US FDA approval of Remsima®8 August 2014
Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic RetinopathyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports